JP3965521B2 - External agent for improving hair - Google Patents
External agent for improving hair Download PDFInfo
- Publication number
- JP3965521B2 JP3965521B2 JP2005380876A JP2005380876A JP3965521B2 JP 3965521 B2 JP3965521 B2 JP 3965521B2 JP 2005380876 A JP2005380876 A JP 2005380876A JP 2005380876 A JP2005380876 A JP 2005380876A JP 3965521 B2 JP3965521 B2 JP 3965521B2
- Authority
- JP
- Japan
- Prior art keywords
- hair
- external preparation
- vitamin
- weight
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
本発明は毛髪を傷めず、皮膚炎も起こさないで白髪のみを金色に染色する効果がある毛髪改善外用剤に関する。The present invention relates to a hair improving external preparation which has an effect of dyeing only white hair in gold without damaging hair and causing dermatitis.
毛髪は表皮細胞が変化したもので、皮膚の角質層の主成分とおなじくケラチンより構成されている。毛髪の色は人種により、黒色、褐色、金色、赤色とその色調はいろいろある。白髪はメラノサイトでメラニンの生成が停止するために起こる現象で、一種の老化現象と思われる。毛幹の構造は、外側から中心に向かつて、毛小皮、毛皮質、毛髄質の3層よりなり、更に毛小皮は3層よりなる。隣接した毛小皮間ばかりでなく、毛皮質の内部構造にも細胞膜複合体がある。細胞膜複合体は毛小皮と毛小皮間、ならびに毛皮質内細胞間の接着に寄与し、更に毛皮質内の水分や蛋白質が溶出したり、逆に外部からの水分、ならびにパーマ剤やヘアーカラー剤などの薬液が、毛髪内部の毛皮質に浸透し作用するための通り道になっているようである。毛皮質は毛小皮の内側にあり、皮質細胞が毛髪の長さ方向に規則正しく並んだ細胞の集団で、細胞膜複合体にかこまれて、毛髪の色を決定するメラニン色素を含む。また毛髪のしなやかさ、強さなどの性質を左右する重用な部分である。毛髄質は毛髪の中心部にあり、空洞となった蜂の巣状の細胞が軸方向に並んでおり、メラニン色素を含んでいる。 Hair is a change of epidermal cells, and is composed of keratin, which is the main component of the stratum corneum of the skin. There are various colors of black, brown, gold and red depending on race. Gray hair is a phenomenon that occurs because the production of melanin stops in melanocytes, and it seems to be a kind of aging phenomenon. The structure of the hair shaft is composed of three layers of hair cuticle, fur, and medulla from the outer side to the center, and further, the hair cuticle is formed of three layers. There are cell membrane complexes not only between adjacent cuticles, but also in the fur structure. The cell membrane complex contributes to the adhesion between the hair coat and between the cuticles and between the cells in the fur. Furthermore, the moisture and proteins in the fur are eluted, and the moisture from the outside, as well as the permanent and hair. It seems that a chemical solution such as a color agent becomes a way for penetrating and acting on the fur inside the hair. The fur is inside the hair dermis and is a group of cells in which cortical cells are regularly arranged along the length of the hair, and it contains a melanin pigment that is surrounded by a cell membrane complex and determines the color of the hair. It is also an important part that affects the properties of hair such as suppleness and strength. The medulla is located in the center of the hair, and the honeycomb cells in the form of cavities are aligned in the axial direction and contain melanin pigment.
白髪はメラノサイトにおいてメラニンの生成が停止する髪の老化現象と思われる。従来は染毛により着色している。染毛により毛髪は損傷を受ける。染毛処理はパラフエニレンジアミンなどの低分子の色素前駆体を毛髪中で酸化重合し、発色させる方法が主である。この処理は過酸化水素を主剤とする酸化剤を用いた酸化反応である。この酸化反応を毛髪中で効率よく行うために、アルカリ剤を用いてPHが高い領域で処理が行われることから、酸化剤、アルカリ剤による損傷を受ける。これら薬液は毛小皮と毛小皮間の細胞膜復合体を通り、毛皮質内の細胞膜複合体を通じて毛髪内部に影響を及ぼし、細胞膜複合体そのものの溶出、毛髪内部の蛋白質の溶出が起こる。毛皮質には、毛髪の水分を保持する役割があるが、細胞膜複合体や内部の蛋白質の溶出によりその水分保持機能が損なわれる。そのため環境の温度変化の影響を受けやすくなり、パサつき、ヘアースタイルのまとまりや、もちの悪さ、枝毛や切れ毛の発生などの現象が起こる。更に毛髪表面を覆っている毛小皮の最表面はF層と呼ばれる脂質の層がある。F層に含まれる分岐脂肪酸により毛髪表面の滑らかな感触に関与する機能を持っている。この脂肪酸はアルカリ性溶液で処理すると加水分解され、結合している脂肪酸が遊離する、これで毛髪表面に存在していた疎水性の膜、F層がなくなり、毛髪がギシギシした感触になる。〔非特許文献1 最新の毛髪科学 松崎貴 他 p229〜236〕 White hair appears to be an aging phenomenon in which melanin production stops in melanocytes. Conventionally, it is colored by hair dyeing. Hair is damaged by hair dyeing. The hair dyeing treatment is mainly performed by oxidative polymerization of a low molecular weight dye precursor such as paraphenylenediamine in the hair to develop a color. This treatment is an oxidation reaction using an oxidizing agent mainly composed of hydrogen peroxide. In order to efficiently perform this oxidation reaction in the hair, the treatment is performed in a region where the pH is high using an alkali agent, and therefore, damage is caused by the oxidant and the alkali agent. These chemical solutions pass through the cell membrane union between the hair skin and the hair skin and affect the inside of the hair through the cell membrane complex in the fur, causing the cell membrane complex itself to elute and the protein inside the hair to elute. The fur has a role of retaining moisture in hair, but its moisture retention function is impaired by elution of cell membrane complexes and internal proteins. For this reason, it is easily affected by changes in the temperature of the environment, and there are phenomena such as dryness, grouping of hairstyles, poor texture, and generation of split ends and cut hairs. Furthermore, the outermost surface of the hair cuticle covering the hair surface has a lipid layer called F layer. The branched fatty acid contained in the F layer has a function related to the smooth feel of the hair surface. When this fatty acid is treated with an alkaline solution, it is hydrolyzed and the bound fatty acid is liberated, so that the hydrophobic film and F layer present on the hair surface disappear, and the hair feels tinged. [Non-Patent Document 1 Latest hair science Takashi Matsuzaki other p229~236]
染毛の薬剤に過敏な人は、染毛により皮膚炎を発症し、染毛のたびに、その症状は悪化する。染毛剤で皮膚炎を起こさない、又染毛により毛髪に損傷を与えない、更に女性羨望の白髪を金色に染毛する外用剤が求められている。 People who are sensitive to hair dyeing agents develop dermatitis due to hair dyeing, and the symptoms worsen with each hair dyeing. There is a need for an external preparation that does not cause dermatitis with a hair dye, does not damage the hair by hair dyeing, and further dyes the white hair of female envy.
白髪は毛髪の老化現象と思われている。発明者は本発明者の外用剤の白髪への塗布により白髪を金色に染毛するのを発見し、老化して弱った白髪に種々の悪い影響のない、又染毛者が染毛剤による皮膚炎を起こさない、白髪を女性羨望の金髪に染毛する外用剤の提供を課題とした。 Gray hair is thought to be an aging phenomenon of hair. The inventor discovered that the hair of the present inventor was applied to the white hair by applying the external preparation of the inventor to the white hair, and had no adverse effects on the aging and weakened white hair. An object of the present invention is to provide an external preparation that does not cause dermatitis and dyes white hair into a female envy blonde.
本発明はコエンザイムQ10、システイン、ビタミンA,C、E,ワクシニアウイルス接種家兎炎症皮膚抽出液を含有する毛髪改善外用剤。 The present invention is an external preparation for improving hair containing coenzyme Q10, cysteine, vitamins A, C, E, vaccinia virus-inoculated rabbit inflammation skin extract .
親水軟膏500重量部に対して、コエンザイムQ10(0.03〜1.2重量部)Lシステイン(0.48〜2.4重量部)、ビタミンA(0.06〜0.36重量部)、ビタミンC(2.0〜8.0重量部)、ビタミンE(0.4〜1.6重量部)、抗アレルギー作用と掻痒に効果のあるワクシニアウイルス接種家兎炎症皮膚抽出液3.6〜14.4単位、3ml〜12ml(0.6〜2.4重量部)、流動パラフイン(4.4〜13.2重量部)を含有する外用剤を作成する。各薬剤の相互間が化学的に安定する為、又毛髪及び皮膚面での薬剤の安定吸収の為ビタミンC、ワクシニアウイルス接種家兎炎症皮膚抽出液以外のコエンザイムQ10、Lシステイン、ビタミンA、ビタミンEは添加物入りの製剤を用いた毛髪及び皮膚改善外用剤。又本発明の外用剤はクリームとして作成したが、軟膏、ローション等の外用剤組成物の形態とすることが可能である。Coenzyme Q10 (0.03 to 1.2 parts by weight) L cysteine (0.48 to 2.4 parts by weight), vitamin A (0.06 to 0.36 parts by weight) with respect to 500 parts by weight of the hydrophilic ointment, Vitamin C (2.0 to 8.0 parts by weight), Vitamin E (0.4 to 1.6 parts by weight), vaccinia virus-inoculated rabbit inflammation skin extract effective for antiallergic action and pruritus 3.6 to An external preparation containing 14.4 units, 3 ml to 12 ml (0.6 to 2.4 parts by weight) and fluid paraffin (4.4 to 13.2 parts by weight) is prepared. Vitamin C, coenzyme Q10 other than rabbit skin inoculated vaccinia virus, L-cysteine, vitamin A, vitamins for chemical stability between each drug and for stable absorption of drugs on the hair and skin E is an external preparation for improving hair and skin using a preparation containing additives. Moreover, although the external preparation of this invention was created as a cream, it can be set as the form of external preparation compositions, such as ointment and lotion.
本発明者は発明者の外用剤が老化して弱った白髪を傷めないで、3〜4ヶ月毛髪に塗布することで、白髪のみを金髪に染毛する効果がある。従来の染毛剤は強酸、強アルカリで処理するので、毛皮質内の細胞膜複合体の損傷、溶出、内部蛋白質の溶出がおこり、毛髪の水分保持機能が低下し、環境の温度の変化を受けやすくなり、髪がパサついたり、ヘアースタイルのまとまりや、もちの悪さ、枝毛、切れ毛が起こる。更に毛皮質のF層がなくなり毛髪がギシギシした感触になる。本発明者の外用剤は強酸,強アルカリ剤を使用せず、毛髪に上記のような損傷をあたえず、むしろ艶がよくなり、生来の美しさを取り戻し、染毛時染毛剤による皮膚炎の発症はない。又1剤1日1回の毛髪、皮膚への塗布により、皮膚には保湿作用、日焼け、しみ、そばかす、老人性色素斑の美白作用、皺とり作用、つるつると滑らかな艶のある皮膚にし、皮膚面特に顔の頬部の血色をよくする効果に加えて、新しく見出した白髪を金髪に染毛する効果をもつ外用剤は今までない。
(試験例1)
白髪を金髪に染毛する試験は男性3名、女性6名で実施した。1日1回毛髪に塗布、約30日で薄く金髪に染まり始め、3〜4ヶ月程で全員金髪に染毛できた。染毛による毛髪の損傷はなく、むしろ艶が出て生来の美しさを取り戻した。本発明者の外用剤による皮膚炎の発生はない。The present inventor has an effect of dyeing only white hair into blond hair by applying it to the hair for 3 to 4 months without damaging the white hair weakened by the inventor's external preparation. Conventional hair dyes are treated with strong acids and strong alkalis, causing damage to the cell membrane complex in the fur, elution, and elution of internal proteins, reducing the moisture retention function of the hair and receiving changes in the temperature of the environment. It becomes easier, and the hair gets dry, the hair style is lumpy, the stickiness, split ends, and the hair ends. Furthermore, the fur layer of F disappears and the hair feels tingling. The external preparation of the present inventor does not use a strong acid or a strong alkali agent, does not give the hair damage as described above, rather becomes glossy, regains its natural beauty, and dermatitis due to a hair dye during hair dyeing. There is no onset of. Also, by applying to the hair and skin once a day, the skin is moisturized, tanned, stained, freckled, whitening of senile pigment spots, moisturizing, smooth and glossy skin. In addition to the effect of improving the color of the skin, especially the cheeks of the face, there has been no external preparation that has the effect of coloring newly found white hair into blond hair.
(Test Example 1)
The test for dyeing gray hair into blond hair was carried out by 3 men and 6 women. Once applied to hair once a day, it began to lightly fade into blonde hair in about 30 days. There was no damage to the hair due to the dyeing, but rather the luster appeared and the natural beauty was restored. There is no occurrence of dermatitis due to the external preparation of the present inventor.
本発明において使用されるコエンザイムQ10は補酵素として生物活性を有し、ミトコンドリアの電子伝達系の構成成分で、ATPの生合成賦活成分としてエネルギーを生み出す働きがある。コエンザイムQ10はユビキノン類(2.3−ジメトキシー5−メチルー6ポリプレニルー1、4ベンゾキノン)の側鎖のイソプレン単位が10である人特有のユビキノン類であり、ユビデカレノン又は補酵素UQ10とも呼ばれている。分子量は863.36で、融点が約48度の黄色から橙黄色の結晶性の粉末で、匂い及び味はない。エーテルに溶けやすく、光によって分解し、着色が強くなる。コエンザイムQ10の添加量としては特に制限されることはないが、好ましくは0.001〜4.0重量部、より好ましくは0.03〜1.2重量部である。これ以上の濃度では皮膚への好影響が向上することが期待できず、又これ以下の濃度では毛髪及び皮膚への好影響が期待されない。 Coenzyme Q10 used in the present invention has biological activity as a coenzyme, is a component of the mitochondrial electron transport system, and has a function of generating energy as a component for activating ATP biosynthesis. Coenzyme Q10 is a ubiquinone peculiar to humans whose isoprene unit in the side chain of ubiquinones (2.3-dimethoxy-5-methyl-6polyprenyl-1,4benzoquinone) is 10, and is also called ubidecalenone or coenzyme UQ10. It is a yellow to orange-yellow crystalline powder having a molecular weight of 863.36 and a melting point of about 48 degrees, and has no smell or taste. Easily soluble in ether, decomposes by light and becomes more colored. The amount of coenzyme Q10 added is not particularly limited, but is preferably 0.001 to 4.0 parts by weight, more preferably 0.03 to 1.2 parts by weight. If the concentration is higher than this, it cannot be expected that the positive effect on the skin is improved, and if the concentration is lower than this, the positive effect on the hair and skin is not expected.
本発明において使用されるシステインは、生体内代謝系において、SH供与体としての役割を果たし、SH酵素の賦活剤として作用する。皮膚代謝の正常化、抗アレルギー、解毒作用がある。システインもしくはその誘導体としても特に限定されるものではないが、L−システインの誘導体としては、N−アセチルーL−システイン、L−ホモシステイン、L−システイン酸、L−ホモシステイン酸、L−システインスルフィン酸、S−スルフイノーL−システイン、S−スルホーL−システイン、シスチンなどを挙げる事が出来る。又L−システインおよびその誘導体の塩としては、塩酸塩、硝酸塩、硫酸塩等の鉱酸塩、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩などのアルカリ金属塩、アルカリ土類金属塩を挙げることが出来る。本発明において、L−システイン、その誘導体またはそれらの塩としてはL−システインが好ましい。 Cysteine used in the present invention plays a role as an SH donor in the in vivo metabolic system and acts as an activator of SH enzyme. Has normal skin metabolism, anti-allergy and detoxification. Cysteine or its derivative is not particularly limited, but examples of L-cysteine derivatives include N-acetyl-L-cysteine, L-homocysteine, L-cysteic acid, L-homocysteic acid, L-cysteine sulfin. Examples thereof include acids, S-sulfinol L-cysteine, S-sulfo L-cysteine, and cystine. Examples of salts of L-cysteine and derivatives thereof include mineral salts such as hydrochloride, nitrate and sulfate, alkali metal salts such as sodium salt, potassium salt, calcium salt and magnesium salt, and alkaline earth metal salts. I can do it. In the present invention, L-cysteine is preferred as L-cysteine, a derivative thereof or a salt thereof.
本発明において使用されるビタミンAは網膜の暗順応を高める作用、皮膚、粘膜の異常乾燥、角化を改善し、疾病に対する抵抗力を増す作用がある。ビタミンA類としては特に限定されるものではないが、その具体例として、レチノール、デヒドロレチノール、酢酸レチノール、パルミチン酸レチノールもしくはこれらの誘導体等が挙げられ、レチノールの類縁化合物であるレチノイドとしてはレチナール、レチニールエステル、レチノイン酸等の誘導体が挙げられる。本発明において、レチノール、その誘導体としてはパルミチン酸レチノールが好ましい。 Vitamin A used in the present invention has an action of increasing dark adaptation of the retina, an abnormal dryness and keratinization of the skin and mucous membranes, and an action of increasing resistance to diseases. Vitamin A is not particularly limited, and specific examples thereof include retinol, dehydroretinol, retinol acetate, retinol palmitate, or derivatives thereof. Retinoids that are analogs of retinol include retinal, Derivatives such as retinal ester and retinoic acid are listed. In the present invention, retinol and its derivative are preferably retinol palmitate.
本発明において使用されるアスコルビン酸もしくはその塩は、当初は抗壊血病作用を有すると考えられてきたが、更に生体内における細胞間基質とコラーゲンの形成維持に必要で、アスコルビン酸の投与により、コラーゲンの増加が見られる。又メラニン色素生成に関与し、チロジンからメラニンへの生成過程を抑制する。更に酸化型の濃色メラニンを還元型の淡色メラニンに変える作用があり、色素の異常沈着を防ぐ。更に蛋白質の代謝、内分泌機能にも関与する重用な物質である。ビタミンC類としては特に限定されるものではないが、その具体例として、L−アスコルビン酸およびその誘導体またはそれらの塩としては、塩酸塩、硝酸塩、硫酸塩等の鉱酸塩、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩等のアルカリ金属塩、アルカリ土類金属塩等を挙げることが出来る。L−アスコルビン酸、およびその誘導体またはそれらの塩としては、L−アスコルビン酸、L−アスコルビン酸ナトリウム、L−アスコルビン酸カリウム、L−アスコルビン酸カルシウム、L−アスコルビン酸マグネシウムなどのL−アスコルビン酸塩、L−アスコルビン酸モノステアレート、L−アスコルビン酸モノパルミテート、L−アスコルビン酸モノオレエート等のアスコルビン酸モノアルキルまたはモノアルケニルエステル類;L−アスコルビン酸ジステアレート、L−アスコルビン酸ジパルミテート、L−アスコルビン酸ジオレエート等のL−アスコルビン酸ジアルキルまたはジアルケニルエステル類;L−アスコルビン酸トリステアレート、L−アスコルビン酸トリパルミテート、L−アスコルビン酸トリオレエート等のL−アスコルビン酸トリアルキルまたはトリアルケニルエステル類;L−アスコルビル硫酸、L−アスコルビル硫酸ナトリウム、L−アスコルビル硫酸カリウム、L−アスコルビル硫酸マグネシウム、L−アスコルビル硫酸カルシウム等のL−アスコルビン酸硫酸エステル類;L−アスコルビルリン酸、L−アスコルビルリン酸ナトリウム、L−アスコルビルリン酸カリウム、L−アスコルビルリン酸マグネシウム、L−アスコルビルリン酸カルシウム等のL−アスコルビン酸リン酸エステル類など;L−アスコルビン酸グリコシド等のアスコルビン酸配糖体などを挙げることが出来る。本発明において、L−アスコルビン酸、その誘導体またはそれらの塩としてはL−アスコルビン酸が好ましい。 Ascorbic acid or a salt thereof used in the present invention was originally considered to have an anti-scurvy effect, but is further necessary for maintaining the formation of intercellular matrix and collagen in vivo, and ascorbic acid is administered by administration. Increase in collagen is seen. It is also involved in melanin pigment production and suppresses the production process from tyrosin to melanin. In addition, it has the effect of changing oxidized dark melanin to reduced light melanin, preventing abnormal pigmentation. Furthermore, it is an important substance involved in protein metabolism and endocrine function. Although it does not specifically limit as vitamin Cs, As the specific example, L-ascorbic acid and its derivative (s) or those salts are mineral salts, such as hydrochloride, nitrate, a sulfate, sodium salt, potassium Examples thereof include alkali metal salts such as salts, calcium salts and magnesium salts, and alkaline earth metal salts. Examples of L-ascorbic acid and its derivatives or salts thereof include L-ascorbic acid salts such as L-ascorbic acid, sodium L-ascorbate, potassium L-ascorbate, calcium L-ascorbate, and magnesium L-ascorbate. L-ascorbic acid monostearate, L-ascorbic acid monopalmitate, ascorbic acid monoalkyl or monoalkenyl esters such as L-ascorbic acid monooleate; L-ascorbic acid distearate, L-ascorbic acid dipalmitate, L-ascorbic acid L-ascorbic acid dialkyl or dialkenyl esters such as dioleate; L-ascorbic acid tristearate, L-ascorbic acid tripalmitate, L-ascorbic acid trioleate, etc. L-ascorbic acid sulfates such as L-ascorbyl sulfate, sodium L-ascorbyl sulfate, potassium L-ascorbyl sulfate, magnesium L-ascorbyl sulfate, calcium L-ascorbyl sulfate; L-ascorbyl sulfate; L-ascorbic acid phosphates such as ascorbyl phosphate, sodium L-ascorbyl phosphate, potassium L-ascorbyl phosphate, magnesium L-ascorbyl phosphate, calcium L-ascorbyl phosphate, etc .; ascorbic acid such as L-ascorbic acid glycoside Examples include glycosides. In the present invention, L-ascorbic acid, its derivative or a salt thereof is preferably L-ascorbic acid.
ビタミンEは妊娠、出産と関係あり、不老長寿の薬と言われ、末梢血管を拡張し血液循環をよくする働きがあり、ビタミンEとコエンザイムQ10は両成分が協力して電子の移動を調整し、体内の酸化反応を抑制するなど、非常に関係の強い成分同士として知られている。ビタミンE類としては、特に限定されるものではないが、その具体例としてはコハク酸トコフエロール、酢酸トコフエロール、ニコチン酸トコフエロールもしくはこれらの誘導体が挙げられる。本発明において、ビタミンE、その誘導体としてはニコチン酸トコフエロールが好ましい。 Vitamin E is related to pregnancy and childbirth, and is said to be a longevity drug. It works to dilate peripheral blood vessels and improve blood circulation. Vitamin E and coenzyme Q10 coordinate the movement of electrons through the cooperation of both components. It is known as a very closely related component, such as suppressing the oxidation reaction in the body. Vitamin E is not particularly limited, and specific examples thereof include tocopherol succinate, tocopherol acetate, tocopherol nicotinate or derivatives thereof. In the present invention, vitamin E and its derivative are preferably tocopherol nicotinate.
ワクシニアウイルス接種家兎炎症皮膚抽出液は皮膚の掻痒、冷感、異常知覚に、腰痛症、神経痛等の痛みに効果があり、抗アレルギー作用もある医薬品である。 Vaccinia virus-inoculated rabbit inflammation skin extract is an effective drug for itching, cooling and abnormal perception of skin, as well as low back pain, neuralgia, and other anti-allergic effects.
以下に実施例を示して本発明を説明するが、本発明は以下の実施例に限定されるものではない。 The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.
【0028】
【実施例】
本発明の外用剤には、クリーム基材として使用される親水軟膏と流動パラフインが使用されている。さらに、成分として、コエンザイムQ10、L−システイン、ビタミンA,C,E,抗アレルギー作用と掻痒に効果のあるワクシニアウイルス接種家兎炎症皮膚抽出液を加えた外用剤である。 [0028]
【Example】
In the external preparation of the present invention, hydrophilic ointment and fluid paraffin used as a cream base are used. Furthermore, it is an external preparation to which coenzyme Q10, L-cysteine, vitamins A, C, E, vaccinia virus-inoculated rabbit inflammatory skin extract effective for antiallergic action and pruritus are added as ingredients.
(実施例1)
毛髪、皮膚改善外用剤は以下の組成で、常法により外用剤を製造した。
NEソフトカプセル(ニコチン酸トコフエロール200mg) 20錠(軟カプセルは除く)
チョコラA(パルミチン酸レチノール) 30ml
アデリール錠(コエンザイムQ10、ユビデカレノン)10mg 300錠(粉砕後)
ハイチオール散32%(Lシステイン) 15g
アスコルビン酸(日本薬局法) 20g
ナブトピン(ワクシニアウイルス接種家兎炎症皮膚抽出液 7.2単位 6ml
流動パラフイン(日本薬局法) 50ml
親水軟膏 (日本薬局法) 500gExample 1
The external preparation for hair and skin improvement had the following composition, and the external preparation was produced by a conventional method.
NE soft capsule (tocopherol nicotinate 200 mg) 20 tablets (excluding soft capsules)
Chocola A (retinol palmitate) 30ml
Adeliel Tablets (Coenzyme Q10, Ubidecarenone) 10mg 300 tablets (after grinding)
Hythiol powder 32% (L cysteine) 15g
Ascorbic acid (Japanese Pharmacy Law) 20g
Nabutopine (Vaccinia virus inoculated rabbit inflammation skin extract 7.2 units 6 ml
Flowing paraffin (Japanese Pharmacy Law) 50ml
Hydrophilic ointment (Japanese Pharmacy Law) 500g
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005380876A JP3965521B2 (en) | 2005-12-07 | 2005-12-07 | External agent for improving hair |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005380876A JP3965521B2 (en) | 2005-12-07 | 2005-12-07 | External agent for improving hair |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007153863A JP2007153863A (en) | 2007-06-21 |
JP3965521B2 true JP3965521B2 (en) | 2007-08-29 |
Family
ID=38238665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005380876A Expired - Fee Related JP3965521B2 (en) | 2005-12-07 | 2005-12-07 | External agent for improving hair |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3965521B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011236191A (en) * | 2010-05-11 | 2011-11-24 | Shunzo Kobayashi | Arteriosclerosis improving agent |
CN107108422A (en) * | 2014-12-22 | 2017-08-29 | 欧莱雅 | 1 (3,4 2 substitution) phenyl 2 (3,4 2 substitution) diphenylphosphino ethane compound and application thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4300370B2 (en) | 2007-03-13 | 2009-07-22 | 春三 小林 | Epithelial improving agent |
JP5026205B2 (en) * | 2007-09-18 | 2012-09-12 | 日本メナード化粧品株式会社 | Hair composition |
-
2005
- 2005-12-07 JP JP2005380876A patent/JP3965521B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011236191A (en) * | 2010-05-11 | 2011-11-24 | Shunzo Kobayashi | Arteriosclerosis improving agent |
CN107108422A (en) * | 2014-12-22 | 2017-08-29 | 欧莱雅 | 1 (3,4 2 substitution) phenyl 2 (3,4 2 substitution) diphenylphosphino ethane compound and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2007153863A (en) | 2007-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7517912B1 (en) | Prostaglandin analog compositions and methods to treat epithelial-related conditions | |
US20060063718A1 (en) | Topical glutathione compositions | |
BRPI0620811A2 (en) | arginine heteromers for topical administration | |
CA2785633C (en) | Topical acyl glutathione formulations | |
JP3965521B2 (en) | External agent for improving hair | |
US20090306163A1 (en) | Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling | |
EP2547317B1 (en) | Topical acyl glutathione formulations | |
US20110160144A1 (en) | Topical Acyl Glutathione Formulations | |
US9629788B2 (en) | Topical glutathione formulations for menopausal skin | |
JPS62142108A (en) | Hair tonic composition | |
KR20230107926A (en) | Cosmetic composition containing peptide mixture | |
TWM656940U (en) | Liposome-coated structure with plant-derived bioactive peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070207 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070409 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070508 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070514 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100608 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130608 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130608 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130608 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130608 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130608 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |